Regeneron Pharmaceuticals Inc. and Intellia Therapeutics Inc. have announced an expanded research collaboration intended to develop additional CRISPR-based gene editing therapies focused on neurological and muscular diseases.
According to a release from Intellia, the expanded partnership seeks to combine Regeneron’s proprietary antibody-targeted adeno-associated virus vectors and delivery systems with Intellia’s proprietary Nme2 CRISPR/Cas9 (Nme2Cas9) systems adapted for viral vector delivery which modify targeted genes.
“We are excited to expand our successful collaboration